Australian people can buy antibiotics in Australia online here: No prescription required and cheap price!

Microsoft word - acci_cia_abstract_2011_millemauldincudesabia

A New Look at Consumers’ and Clinicians’ Options in Smoking Cessation: Smokeless
Tobacco, Nicotine Replacement Therapy, Zyban , Chantix and other Interventions
Jason D. Miller, Oregon State University1
Teresa A. Mauldin, University of Georgia2
Brenda Cude, University of Georgia3
Joseph J. Sabia, U.S. Military Academy at West Point4
In recent years, a debate has emerged in the literature over the potential for smokeless tobacco to serve as an aide in smoking cessation or prevention. Some cross-sectional evidence supported the reform of smokeless tobacco regulation, although this has been contested. Unusually high smokeless tobacco incidence has emerged in Sweden, perhaps due to resurgence in the popularity of "snus", a spit-free smokeless tobacco product. Tobacco-related cancers are relatively infrequent in Sweden and snus is widely marketed as a cigarette alternative by Swedish firms such as Northerner Scandinavia, Inc. ( Even more recently, American tobacco companies such as Altria Group1 and R.J. Reynolds2 have begun to market domestic versions of snus and other new smokeless tobacco products. This study utilized individual level data to estimate the effects of smokeless tobacco use on smoking behavior and incorporated meta-analysis of the research conducted on established cessation aids. Objective
The goal of this study was to evaluate the potential of smokeless tobacco to serve as a viable choice for consumers, clinicians, and policymakers seeking to reduce the use of flammable tobacco, which has been documented as having significantly more harmful effects (although both have been reported to cause morbidity and mortality by the Surgeon General). Hypotheses
RH1: Onset of smokeless tobacco use increases the likelihood of smoking cessation over time among young American smokers. RH2: Increasing the level of smokeless tobacco consumption increases the likelihood of smoking cessation over time among young Americans who already use both cigarettes and smokeless tobacco ("dual users"). RH3: Changes to the probability of successful smoking cessation associated with smokeless tobacco use is comparable in magnitude to established cessation tools such as Chantix , nicotine replacement therapy (NRT) and Data & Methods
This study was quasi-experimental in design and made use of a large nationally representative sample from the National Longitudinal Survey of Adolescent Health (Waves I and II). Depending on the particular model in question, the usable sample size varied, but remained near 1,000. Bayesian missing data techniques were used when a reasonably small amount of missingness was found. In addition, outcomes were compared with clinical evaluations of existing cessation tools, such as Chantix , Zyban , NRT, and various combinations of these treatments. In the design phase the propensity-score matching (PSM) technique -a conditional probability used to                                                             1 Altria Group is the parent company of Philip Morris U.S.A., which additionally owns U.S. Smokeless Tobacco Company, John Middleton, Philip Morris Capital Corporation, Altria Client Services and others, as of April, 2011. Altria Group is perhaps best known for their Marlboro line of cigarettes, chewing tobaccos, snus, and other new to market smokeless tobacco confections. 2 R.J. Reynolds is the maker of the Camel line of cigarettes, snus, and other new to market smokeless tobacco confections.  weight respondents – was applied to balance those in the sample who constituted the quasi-treatment with the quasi-control groups. This technique was famously used in the analysis of tobacco litigation to "promote honesty" by balancing the groups without reference to the outcome. The spider plot illustrates enormous improvement in balance following use of the PSM weights. Subsequently, a probit model adapted from the literature was estimated with a cross-section of respondents. Finally, probit, logit, and mixed models with fixed effects were estimated using longitudinal data and regression diagnostics were performed to examine heteroskedasticity, autocorrelation, and potential misspecification. Results & Conclusions
These findings generally failed to support the notion that smokeless tobacco has potential to aid consumers in smoking cessation. This result was consistent across models, alternate measurements of smokeless tobacco use and smoking behavior. Although dual-users may experience unique benefits from increased smokeless tobacco, it was clear that pharmaceutical treatments are generally more effective. A notable exception was in the case of those who dually smoke cigarettes and use smokeless tobacco. Among this sub-population increased smokeless tobacco use was a significant predictor of smoking cessation. It is not clear that smokeless tobacco warrants favorable treatment by policymakers and future research among dual users is warranted if we are to understand their behavior. References
Ault, R., Beard, T., Jackson, J., & Saba, R. (2005). On the (mis) use of cross-price effects to gauge the effectiveness of smokeless tobacco in smoking cessation. The European Journal of Health Economics, 6(1), 83-86. Ault, R. W., Ekelund, R. B., Jackson, J. D., & Saba, R. P. (2004). Smokeless tobacco, smoking cessation and harm reduction: an economic analysis. Applied Economics, 36(1), 17. Bask, M., & Melkersson, M. (2003). Should one use smokeless tobacco in smoking cessation programs? The European Journal of Health Economics, 4(4), 263-270. Bask, M., & Melkersson, M. (2004). Rationally addicted to drinking and smoking? Applied Economics, 36(4), 373-381. Becker, G. S., Grossman, M., & Murphy, K. M. (1994). An Empirical Analysis of Cigarette Addiction. American Economic Review, 84(3), 396-418. Becker, G. S., & Murphy, K. M. (1988). A Theory of Rational Addiction. Journal of Political Economy, 96(4), 675. Benowitz, N. L., & Gourlay, S. G. (1997). Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. Journal of the American College of Cardiology, 29(7), 1422-1431. Bolinder, G., Alfredsson, L., Englund, A., & de Faire, U. (1994). Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. American Journal Of Public Health, 84(3), 399-404. Cahill, K., & Ussher, M. (2007). Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane database of systematic reviews (Online)(3). Chaloupka, F. J., & Tauras, J. A. (2004). The Impact of Nicotine Replacement Therapies on Cigarette Demand. Journal of Economics and Finance, 28(3), 395-403. Chaloupka, F. J., Tauras, J. A., & Grossman, M. (1997). Public Policy and Youth Smokeless Tobacco Use. Southern Economic Journal, 64(2), 503-516. Chu, V. (2006). Nicotine Replacement Therapy for Tobacco Use Cessation: Reference Table. Journal of Pharmacy Practice, 19(5), 297. Ebbert, J. O., Burke, M. V., Hays, J. T., & Hurt, R. D. (2009). Combination treatment with varenicline and nicotine replacement therapy. Nicotine & Tobacco Research, 11(5), 572-572. Foulds, J., Ramstrom, L., Burke, M., & Fagerstrom, K. (2003). Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tobacco Control, 12(Journal Article), 349. Gilljam, H., & Galanti, M. R. (2003). Role of snus (oral moist snuff ) in smoking cessation and smoking reduction in Sweden. Addiction, 98(9), 1183-1189. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., et al. (2006). Varenicline, an {alpha} 4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA, 296(1), 47-47. Hays, J., Croghan, I., Schroeder, D., Offord, K., Hurt, R., Hughes, J., Stead, L., & Lancaster, T. (2010). Antidepressants for smoking cessation. The Cochrane Library (Cocharne Review reprint). Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., et al. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 340(9), 685-685. Keeler, T. E., Marciniak, M., & Hu, T.W. (1999). Rational Addiction and Smoking Cessation: An Empirical Study. Journal of Socio-economics, 28(5), 633-643. Labeaga, J. (1999). A double-hurdle rational addiction model with heterogeneity: Estimating the demand for tobacco. Journal of Econometrics, 93(1), 49-72. Ramstrom, L. M., & Foulds, J. (2006). Role of snus in initiation and cessation of tobacco smoking in Sweden. British Medical Journal, 15(3), 210. Rubin, D.B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika. Rubin, .D.B. (1984). Reducing bias in observational studies using subclassification on the propensity score. Journal of the American Statistical Association. Rubin, D.B, (2001). Using propensity scores to help design observational studies: application to the tobacco litigation. Health Services and Outcomes Research Methodology, 2(3), 169-188. Smith, S., McCarthy, D., Japuntich, S., Christiansen, B., Piper, M., Jorenby, D., et al. (2009). Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Archives of Internal Medicine, 169(22), 2148. Stratton, K. R. (2001). Clearing the smoke: assessing the science base for tobacco harm reduction. Washington, D.C.: National Academy Press. Suranovic, S. M., Goldfarb, R. S., & Leonard, T. C. (1999). An economic theory of cigarette addiction. Journal of Health Economics, 18(1), 1-29. Tauras, J., Powell, L., Chaloupka, F., & Ross, H. (2007). The Demand for Smokeless Tobacco among Male High School Students in the United States: The Impact of Taxes, Prices and Policies. Applied Economics, 39(1-3), 31-41 Endnotes
________________________________ 1 Ph.D. Student, Applied Economics, Oregon State University, 5052 SW Technology Loop, Corvallis, OR 97333, 2 Associate Professor, Department of Housing and Consumer Economics, University of Georgia, 203-B Dawson Hall, Athens, GA 30602, 3 Professor, Department of Housing and Consumer Economics, University of Georgia, 205 Dawson Hall, Athens, GA 30602, 4 Assistant Professor, Department of Social Sciences, United States Military Academy, West Point, NY, 10996,


CURRICULUM VITAE Alex Jovencio Pena Makalinao ASSOCIATED SITES California Hematology Oncology Medical Group California Hematology Oncology Medical Group RESEARCH EXPERIENCE  Phase II Trial in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer.  Double-Blind, Placebo-Controlled, prevention of Acute & Delayed Chemotherapy-Induced Emesis.  Double-Blind, Placebo-Co

Pii: s0264-410x(00)00183-3

Safety evaluation of a recombinant myxoma-RHDV virusinducing horizontal transmissible protection against myxomatosisJuan M. Torresa,*, Miguel A. RamõÂreza, MoÂnica Moralesa, Juan BaÂrcenaa,BeleÂn VaÂzqueza, Enric EspunÄab, Albert PageÁs-ManteÂb, Jose M. SaÂnchez-VizcaõÂnoaaCentro de InvestigacioÂn en Sanidad Animal (CISA-INIA), Valdeolmos, 28130 Madrid, SpainReceived 14 Feb

Copyright © 2010-2014 Find Medical Article